Intuitive Surgical's Double Blow: FDA Nod for a Rival and a Stubborn Forecast Push Shares Toward a Floor
Published on 07/22/2026 at 18:33 | Redaktion boerse-global.de
The past week has delivered a one-two punch to Intuitive Surgical that has left the robotics pioneer clinging to its 52-week low. Shares of the da Vinci maker slipped another 1.61 percent on Wednesday to €302.00, landing just 0.80 percent above the €299.60 trough touched on Monday. The slide reflects not one but two distinct headwinds that have converged with brutal timing.
On the competitive front, the US Food and Drug Administration on July 22 cleared Johnson & Johnson's Ottava robotic system for upper-abdominal procedures, including gallbladder removals and gastric bypass surgeries. The approval thrusts J&J directly into da Vinci's turf, joining Medtronic's Hugo system in a rapidly thickening competitive landscape. For a company that has long enjoyed near-monopoly pricing power in robotic surgery, the implications are hard to ignore.
The second blow landed two days earlier, on July 20, when Intuitive Surgical reported second-quarter results that, by any operational measure, looked strong. Revenue climbed 19 percent to $2.89 billion, GAAP net income rose 24 percent to $818 million, and procedure growth hit 15 percent. The installed base of da Vinci systems swelled to 11,710, with 468 new shipments in the quarter — half of them the next-generation da Vinci 5 model. The Ion lung-biopsy device posted a 36 percent usage increase.
Yet the market punished the stock by as much as 13 percent after the numbers crossed the wires. The culprit was not the quarter itself but the unchanged full-year guidance. Management kept its 2026 procedure-growth target at 13.5 to 15.5 percent, even though the first half already ran at the upper end of that range. Investors who had been hoping for an upgrade were left disappointed.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Chief executive Dave Rosa explained that the expiry of enhanced ACA health-insurance subsidies had exerted a "moderate negative impact" on domestic procedure volumes. That admission, buried in the earnings release, triggered a cascade of analyst revisions. Within 48 hours, JPMorgan slashed its price target from $550 to $450, TD Cowen cut from $585 to $520, and Wells Fargo set a new mark at $487. All three maintained their ratings, but the direction of travel was unmistakable.
The guidance caution also reflects a structural shift that has been weighing on the sector: GLP-1 weight-loss drugs are curbing demand for bariatric surgery, a key growth driver for da Vinci. The company's own cost-reduction program, set to begin in the first half of 2027, signals that management is bracing for margin pressure. Longer instrument lifecycles, a push toward leasing — already at 54 percent of placements — and the introduction of the cheaper XiR model all point to a market where pricing power is eroding.
Adding to shareholder unease, Intuitive Surgical filed a shelf registration on July 22 for $1.77 billion related to an employee stock plan. While the filing creates flexibility for equity grants to staff, it also introduces a potential dilution risk for existing holders. Over the past three years, the stock has delivered a total return of just 5.8 percent, and 7.7 percent over five years — modest figures for a company with Intuitive's operating momentum.
The technical picture has deteriorated sharply. The relative strength index stands at 31.8, deep in oversold territory, after a 10.95 percent drop in just seven trading sessions. From the 52-week high of €516.50 reached in early January, the stock has now lost 38.26 percent. The gap between the current price and that January peak stands at over 40 percent.
Valuation remains a point of contention. The stock trades at a price-to-earnings ratio of 42.1, which Trefis calculates would require annual revenue growth of 14.1 percent over four years to justify — a hurdle that looks achievable given the recent 21 percent growth rate and the three-year average of 18.1 percent. Simply Wall St pegs the shares as 15.7 percent undervalued, while one Motley Fool-cited target of roughly $498 implies about 30 percent upside from recent levels.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Yet the market is looking past the math and focusing on the narrative shift. The competitive landscape is no longer a one-player game, and the growth trajectory for US elective procedures faces headwinds that management itself has acknowledged. The coming weeks will test whether the Ottava approval proves to be a genuine market-share threat or a temporary distraction, and whether the procedure-growth deceleration is cyclical or structural.
In a telling contrast, the smaller rival Vicarious Surgical voted on July 21 to liquidate after burning through roughly $300 million without bringing a market-ready product to fruition. The episode underscores just how capital-intensive the surgical robotics business remains — and how high the barriers to entry are. But it also highlights that even a dominant incumbent is not immune to the market's shifting mood when the growth narrative begins to fray.
Ad
Intuitive Surgical Stock: New Analysis - 22 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
